Diadema Partners LP Vaxcyte, Inc. Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 10,000 shares of PCVX stock, worth $797,400. This represents 0.35% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$797,400% of portfolio
0.35%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
349Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$954 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$843 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$793 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$693 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$495 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.73B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...